SCHEDULE: Glazer Capital Reports 0% Stake in Y-mAbs Therapeutics

Glazer Capital, LLC and Paul J. Glazer have filed an amended Schedule 13G indicating they no longer beneficially own shares of Y-mAbs Therapeutics, Inc.

Summary

• Glazer Capital, LLC and Paul J. Glazer, as Reporting Persons, filed an Amendment No. 1 to Schedule 13G concerning Y-mAbs Therapeutics, Inc. Common Stock.
• The filing indicates that as of September 30, 2025, the Reporting Persons beneficially own 0.00 shares of Y-mAbs Therapeutics, Inc.
• This beneficial ownership represents 0.00% of the class of securities.
• Neither Glazer Capital, LLC nor Paul J. Glazer hold any sole or shared voting power (0.00) or sole or shared dispositive power (0.00) over Y-mAbs Therapeutics, Inc. shares.
• The Reporting Persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of a change in beneficial ownership to 0%. It does not contain positive or negative operational or financial news about the issuer.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a change in beneficial ownership by an investment manager. It does not provide specific insights into broader industry trends or competitive landscape for Y-mAbs Therapeutics, Inc. beyond indicating a fund's exit from its position.

Stakeholder Impact

• Shareholders: May note the exit of Glazer Capital, LLC from its position, which could be interpreted in various ways depending on prior market sentiment towards the fund's involvement.

Key Dates

Keywords

Y-mAbs Therapeutics, Glazer Capital, Paul J. Glazer, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Manager